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Abstract: Smallpox was eradicated more than 30 years ago, but heightened concerns over 
  bioterrorism have brought smallpox and smallpox vaccination back to the forefront. The previously 
licensed smallpox vaccine in the United States, Dryvax® (Wyeth Laboratories, Inc.), was highly 
effective, but the supply was insufficient to vaccinate the entire current US population. Addition-
ally, Dryvax® had a questionable safety profile since it consisted of a pool of vaccinia virus strains 
with varying degrees of virulence, and was grown on the skin of calves, an outdated technique that 
poses an unnecessary risk of contamination. The US government has therefore recently supported 
development of an improved live vaccinia virus smallpox vaccine. This initiative has resulted 
in the development of ACAM2000™ (Acambis, Inc.™), a single plaque-purified vaccinia virus 
derivative of Dryvax®, aseptically propagated in cell culture. Preclinical and clinical trials reported 
in 2008 demonstrated that ACAM2000™ has comparable immunogenicity to that of Dryvax®, 
and causes a similar frequency of adverse events. Furthermore, like Dryvax®, ACAM2000™ 
vaccination has been shown by careful cardiac screening to result in an unexpectedly high rate of 
myocarditis and pericarditis. ACAM2000™ received US Food and Drug Administration (FDA) 
approval in August 2007, and replaced Dryvax® for all smallpox vaccinations in February 2008. 
Currently, over 200 million doses of ACAM2000™ have been produced for the US Strategic 
National Stockpile. This review of ACAM2000™ addresses the production, characterization, 
clinical trials, and adverse events associated with this new smallpox vaccine.
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Introduction
After a devastating battle spanning centuries, smallpox was eliminated globally in 1980 as a 
result of the successful eradication program by the World Health Organization (WHO). The 
live vaccinia virus vaccine, Dryvax® (New York City Board of Health [NYCBH] strain) 
was one of the vaccines used during the worldwide vaccination campaign. Dryvax® was 
prepared by harvesting live virus from lesions on the skin of infected cows; thus, sterility 
of the vaccine was always questionable.1 Adverse events ranging from mild systemic 
symptoms such as fever, myalgia, and headaches, to serious adverse events including 
generalized vaccinia, eczema, encephalitis, and even fatality, were seen after Dryvax® 
vaccinations.2 Therefore, following eradication, smallpox vaccination ended for the public 
in 1972 and for the military in 1989 in the US.1 The last time Dryvax® was manufactured 
was in 1978 by Wyeth Laboratories (Marietha, PA), and there were only 15 million doses 
of the smallpox vaccine left after the suspension of all smallpox vaccinations.
In the 1990s, the US became more sensitive to the possible threat of an accidental or 
intentional release of smallpox. A directive issued by President Clinton in 1995 initiated Dovepress
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  counterterrorism programs in several federal agencies, which 
resulted in a strategy to re-institute smallpox vaccination 
should it become necessary.3 Vaccination with live vaccinia 
virus was instrumental to the success of the eradication 
  campaign and, for that reason, a live vaccinia vaccine approach 
was chosen. Among the vaccinia strains used for worldwide 
eradication in the 20th century, Dryvax®, consisting of the 
NYCBH strain, was thought to be the safest, having the fewest 
adverse events.4 Because of advances in vaccine production 
technology, a cell culture-based mode of propagation could 
replace growth on the skin of cows. Growth in culture allows 
for many improvements in the quality of the vaccine product, 
such as eliminating possible contaminants and reducing lot-to-
lot variation. Nevertheless, Dryvax® was a mixed population of 
vaccinia strains, and growth of this pool in cell culture might 
have unintentionally provided selective pressure promoting 
virulent strains. Furthermore, vaccination with a mixed popula-
tion could allow more virulent strains to propagate within the 
host, leading to an increase in the incidence of complications. 
To this end, Acambis, Inc. (Cambridge, MA) was contracted 
by the US government to develop and produce a new vaccine 
from a single purified isolate of vaccinia virus. This article 
reviews the development, safety profile, immunogenicity, and 
protective efficacy of ACAM2000™. In addition, the serious 
adverse events caused by ACAM2000™ will be discussed.
Development and safety  
of ACAM2000™
Acambis investigators isolated six individual clones by 
plaque purification from a pool of 30 vials (3000 doses) of 
Dryvax®, NYCBH. These clones, designated CL1 through 
CL6, were tested for virulence in comparison with Dryvax®. 
The virulence tests included the diameter of erythema 
and lesions on day eight after scarification of rabbit skin.5 
The rabbit scarification model mimics the vaccine “take” 
observed following human vaccination with Dryvax®, in 
that a lesion forms at the site of scarification because of 
local replication of vaccinia virus.6 A second virulence test 
measured survival time and replication in brain tissue after 
intracerebral injection of suckling mice.5 The intracerebral 
suckling mouse model is useful in gauging virulence because 
strains with a higher incidence of post-vaccinia encephalitis 
have greater neurovirulence in mice.7–9 Among the six 
Dryvax®-derived clones, there was significant variation in 
virulence. Several of the clones were significantly more 
virulent than Dryvax® in one or more of the assays, with 
CL3 being the most virulent clone. CL2 had a profile most 
similar to Dryvax® overall with respect to lesion size and 
neurovirulence, and was therefore chosen as the new vaccine 
strain, named ACAM1000 (see Figure 1).5
Dryvax®
(Vaccinia virus pool)
Old US vaccine
stockpile
Isolated clones
tested for virulence
Early version of
new vaccine
New US vaccine
stockpile
Clone 1
Clone 2
Clone 3
Clone 4
Clone 5
Clone 6
MRC-5 cell
Passage Passage
Vero cell
= Most virulent clone
ACAM1000 ACAM2000TM
Figure 1 Dryvax® consists of a mixed pool of vaccinia virus NYCBH strain. Six vaccinia virus clones were isolated and purified. These were all tested and Clone 2 (CL2) was 
found to have a virulence profile most closely resembling that of Dryvax®. This clone was propagated on MRC-5 cells and purified to produce the vaccine, named ACAM1000™. 
Additional expansion was carried out on Vero cells to produce more than 200 million vaccine doses, and the vaccine was renamed ACAM2000™.
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The goal of the Acambis vaccine initiative was to produce 
a vaccine that would meet or exceed the safety profile of 
Dryvax® without sacrificing efficacy. As a test of these 
criteria, preclinical and clinical safety and efficacy studies 
compared vaccination of ACAM1000 with Dryvax®. The 
virulence of ACAM1000 and Dryvax® were evaluated by 
monitoring survival following intracerebral injection of suck-
ling mice. Mice inoculated with ACAM1000 had a mortality 
rate that was up to 50% lower than that of Dryvax® in repeated 
experiments.10 In a comparison of intrathalamic injection 
of rhesus macaques with 1.25 × 107 pfu of ACAM1000 or 
4.9 × 107 pfu of Dryvax®, 50% of the rhesus macaques in 
the Dryvax® group died, whereas there were no deaths in the 
ACAM1000 group, with the investigators suggesting that 
ACAM1000 is less virulent than Dryvax®.10 The difference 
in virulence could be because of the fourfold larger amount 
injected into the primates in the Dryvax® group; however, 
two additional primates were given intrathalamic injection 
of 1 × 108 pfu of ACAM1000 and did not fall ill. Therefore, 
ACAM1000 appears to be at least as safe, if not safer, than 
Dryvax® in animal models.
Efficacy of the vaccinia clones ACAM1000 and CL3 
(a virulent clone derived from Dryvax®) was compared 
with that of Dryvax® using a mouse intranasal challenge 
model.10 Each vaccine showed comparable survival time 
after intranasal challenge of mice with vaccinia virus strain 
WR (Western Reserve) and similar protection against weight 
loss following challenge with cowpox virus. The major 
weakness of the vaccinia virus WR model is that the same 
virus, albeit a different strain, was used as a challenge virus. 
Consequently, this challenge model does not demonstrate 
the ability of the live vaccinia virus vaccines to cross protect 
against different viruses within the Orthopoxvirus family. 
This issue is addressed, however, by the use of cowpox 
virus for challenge, which protected against weight loss and 
death.10 ACAM1000 or CL3 vaccination of mice induced 
either comparable or increased levels of both neutralizing 
antibodies and T-cell responses compared with Dryvax®, 
indicating that ACAM1000 induced acceptable immune 
responses.10 These results also demonstrate that virulence 
factors present in CL3, but absent from ACAM1000, do 
not result in a measurable difference in immunogenicity or 
efficacy in the mouse model.
In light of the apparent similarity in safety and efficacy 
of ACAM1000 and Dryvax® in animal models, two Phase I 
  clinical trials were set up with 30 individuals receiving the 
Dryvax® vaccine and a total of 100 receiving ACAM1000.6,10 
A pilot vaccine lot of 750,000 doses of ACAM1000 
  propagated on MRC-5 cells, a human embryonic lung 
fibroblast cell line, were produced before this trial. The 
  vaccine was administered by scarification with 15 strokes of 
a bifurcated needle through a droplet of solution containing 
1 × 108 pfu/mL of virus. The results of this study showed 
that ACAM1000 was similar to Dryvax® in that it elicited 
a 100% take-rate, 100% seroconversion, and a comparable 
T-cell response.10
Considering the success of the ACAM1000 vaccine in 
preclinical and clinical tests, as well as the growing concern 
of terrorist threats subsequent to the attacks in September 
of 2001, the US Government increased their contract with 
Acambis to 209 million vaccine doses. To produce this large 
quantity with as few passages of ACAM1000 as possible, 
Acambis partnered with Baxter BioScience (Deerfield, IL) 
to utilize their large-scale production technology. The new 
strategy entailed inoculating Vero (African green mon-
key kidney epithelial) cells with a master seed stock of 
ACAM1000 (passage 7) and growing them on microcarrier 
beads in serum-free medium in large 1200-L bioreactors for 
three passages (see Figure 1).6 The resulting virus stock, 
renamed ACAM2000™ (passage 10), was partially puri-
fied of cell debris by large-pore depth filtration, and cel-
lular genomic material was digested. The lots were tested 
for bacterial, fungal, and viral contamination and for both 
human and bovine pathogens.
Double-stranded DNA viruses, such as vaccinia virus, 
typically have very low rates of mutation from one passage 
to the next. It is therefore not surprising that the fidelity of 
the nucleotide sequence was maintained, with passage 10 
of ACAM2000™ having an identical genetic sequence to 
passage 7 of ACAM1000.6 In contrast, the vaccinia strain, 
VACV-DUKE, was isolated from a patient with progressive 
  vaccinia following Dryvax® vaccination, and was found to 
have genomic sequence differences from ACAM2000™.11 
Unlike ACAM2000™, VACV-DUKE contains a full-length 
copy of the interferon (IFN)-α/β receptor, which is also 
  present in the virulent clone 3 (CL3). Deletion of this receptor 
from vaccinia virus WR causes attenuation as measured by 
intranasal inoculation of mice.12 Additionally, 625 mutational 
differences were found between CL3 and ACAM2000™.13 
These studies also revealed that four virulence factors present 
in CL3 were absent in ACAM2000™: INF-α/β binding pro-
tein, tumor necrosis factor (TNF) receptor, an ankyrin repeat 
ortholog, and an elongated thymidylate kinase. Therefore, 
Dryvax® contains a sub-population that produces specific 
virulence factors, evidence suggesting that ACAM2000™ 
will be safer than Dryvax®. A possible caveat however is that Dovepress
Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
74
Nalca and Zumbrun
ACAM2000™ could be less effective than Dryvax® because 
the missing virulence factors are not presented to the host. 
Nonetheless, ACAM2000™ retains 100% identity in four 
open reading frames (ORFs), ORF-99, -161, -167, and -198, 
known to be important for conferring protective immunity 
in Copenhagen and WR strains.14–17
Efficacy of ACAM2000™ 
in animal models
To advance ACAM2000™ to human trials, first a similarity 
to ACAM1000 and Dryvax® with regard to pathogenicity, 
induction of immunity, and efficacy had to be demonstrated 
in animal models. ACAM1000 and ACAM2000™ were both 
less virulent than Dryvax® in three- to four-day-old suckling 
mice administered an intracerebral (IC) inoculation with 
regard to both survival and LD50 analysis.6 ACAM1000 and 
ACAM2000™ had survival rates of approximately 65%–
70% compared with 10%–20% in the Dryvax®-vaccinated 
  group. Moreover, the lesion size and erythema resulting 
from either ACAM1000 or ACAM2000™ scarification 
of rabbit skin was less than or equal to that of Dryvax®.6 
Protective efficacy of ACAM1000, ACAM2000™, and 
Dryvax® vaccination was compared after vaccinia virus 
WR challenge of BALB/C mice, and the three vaccines 
provided comparable protection with regard to survival time 
and amount of vaccine required to achieve 50% survival 
in a group (see Table 1). Of note, scarification of BALB/C 
mice with ACAM1000 and ACAM2000™ induced more 
abundant neutralizing antibodies than Dryvax®, and all three 
groups had equivalent T-cell responses following scarifica-
tion of BALB/C mice.6
Because of the eradication of smallpox, the true effi-
cacy of vaccine candidates cannot be measured. In 2002, 
the FDA established the Animal Rule, such that it can rely 
on the results of animal studies where human trials are 
not possible or ethical. The most rigorous and clinically 
relevant model for testing the efficacy of smallpox vaccine 
candidates is by monkeypox virus challenge of cynomolgus 
macaques.18–21 Vaccination of cynomolgus macaques with 
ACAM2000™ or Dryvax® resulted in a 100% take-rate and 
comparable sizes of vaccination site lesions.22 Additionally, 
Dryvax® and ACAM2000™ vaccination induced sero-
conversion in 100% of the cynomolgus macaques and the 
levels of neutralizing antibodies were comparable between 
groups. Both vaccines completely protected against death 
and fever, and almost fully protected against development 
of rash and presence of virus in throat swabs after intrave-
nous challenge with an otherwise uniformly lethal dose of 
monkeypox virus (see Table 1). There were more incidents 
of breakthrough lesions near the inoculation site in the 
Dryvax® group (three of eight) than in the ACAM2000™ 
group (one of eight). Additionally, there was breakthrough 
oral shedding in the Dryvax® vaccinated group (three of 
eight). However, nearly three times more vaccine was given 
to the ACAM2000™ group, thus relative efficacy cannot 
fairly be compared, especially considering that fivefold dif-
ferences in ACAM2000™ vaccine doses produce markedly 
different levels of take and antibody response in humans.23 
Overall, this study showed that ACAM2000™ provided 
protection comparable with Dryvax® in a rigorous challenge 
model, but that neither vaccine offered sterilizing immunity 
in 100% of the subjects.
ACAM2000™ clinical trials
One hundred vaccinia naïve human subjects were inoculated 
with 7.7 × 107 pfu/mL of ACAM2000™ in a Phase I trial, 
with exclusion and inclusion criteria matching that of the 
previous ACAM1000 and Dryvax® trials (ie, 18–29 years 
of age, vaccinia-naïve, and with no contraindications to 
vaccination). ACAM2000™ vaccination resulted in a 
99% take-rate, and lesion sizes and induction of neutral-
izing antibodies comparable with that of ACAM1000.6 In 
another Phase I trial, 30 vaccinia-naïve subjects per group 
were inoculated with 1 × 108 pfu/mL of ACAM2000™, 
ACAM1000, or Dryvax®.24 All subjects had a successful 
skin reaction or “take” and the majority had positive anti-
Table 1 ACAM2000™ efficacy studies in animal models
Animal species Vaccinations  Vaccination  
dose
Challenge  
virus and dose
Challenge route Outcome Reference
BALB/C mice ACAM2000™  
ACAM1000  
Dryvax®
For all 104,105,  
106 or  
107 pfu/mL
Vaccinia virus-  
WR strain  
100 × LD50
IN All vaccines provided  
equivalent protection
Monath et al6
Cynomolgus 
macaques
ACAM2000™  
Dryvax®
4.4 × 108 pfu/mL 
1.5 × l08 pfu/mL
Monkeypox  
virus/Zaire79  
3.8 × l07 pfu/mL
IV Dryvax® and ACAM2000™  
Provided equivalent 
  protection
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body (96.7% of ACAM2000™ and Dryvax® groups, and 
90% of ACAM1000 subjects seroconverted) and T-cell 
responses. ACAM1000 and ACAM2000™ have equivalent 
safety and efficacy profiles, therefore a request was made 
by the US Government in 2003 for future studies to be done 
with ACAM2000™ alone.
Two Phase II trials were carried out to compare 
ACAM2000™ and Dryvax®, one in vaccinia-naïve subjects 
and one in previously vaccinated “experienced” subjects. 
To determine the lowest effective dose, defined as having a 
greater than 90% take-rate, these trials compared Dryvax® at 
the standard dose, to four different doses of ACAM2000™.23 
The dose of Dryvax® was 1.6 × 108 pfu/mL and the starting 
dose of ACAM2000™ was 2.3-fold lower at 6.8 × 107 pfu/mL. 
Additional groups were given 1:5, 1:10, or 1:20 dilutions 
of ACAM2000™. All naïve individuals vaccinated with 
Dryvax® or the highest dose of ACAM2000™ experienced 
a take, and 96% and 94% seroconverted, respectively, with 
comparable levels of neutralizing antibody. In contrast, 
the naïve groups receiving 1:5, 1:10, or 1:20 dilutions of 
ACAM2000™ had take-rates of 86%, 80%, and 59%, 
respectively; below the threshold set for efficacy. Therefore, 
vaccination with 6.8 × 107 pfu/mL of ACAM2000™ is as 
effective as a 1.6 × 108 pfu/mL dose of Dryvax® in vaccinia-
naïve subjects. However, in contrast with Dryvax®, which 
causes a cutaneous reaction in over 97% of vaccinees even 
when diluted up to 10-fold (approximately 1 × 107 pfu/mL), 
a fivefold dilution (1.4 × 107 pfu/mL) of ACAM2000™ failed 
to offer the requisite 90% take-rate in the vaccinia-naïve 
group.25 The Phase II clinical trial in vaccinia-experienced 
subjects showed that the group receiving the highest dose of 
ACAM2000™ (6.8 × 107 pfu/mL) had an 88% take-rate, com-
pared with 100% in the Dryvax® group (1.6 × 108 pfu/mL). 
Therefore, ACAM2000™ was not as effective for revaccina-
tion as Dryvax®, possibly because the dose of ACAM2000™ 
was more than two-fold less than that of Dryvax®. Unfortu-
nately, the doses of ACAM2000™ and Dryvax® were not the 
same in a number of preclinical and clinical studies, which 
complicates the results because two- or more-fold differences 
could result in significantly different outcomes.
Two Phase III trials were set up comparing ACAM2000™ 
(with doses ranging from 1.3–2.2 × 108 pfu/mL) to Dryvax® 
(1.5 × 108 pfu/mL); one trial for vaccinia-naïve subjects 
and the other trial for vaccinia-experienced subjects.5,24 In 
vaccinia-naïve subjects, the take-rates were 96% and 99% 
for ACAM2000™ and Dryvax®, respectively, indicating 
that both formulations were effective, although the anti-
body titers of ACAM2000™ vaccinated subjects were 
inferior to those receiving Dryvax®. In the Phase III trial 
for vaccinia-experienced subjects, the ACAM2000™ and 
Dryvax® groups had 84% and 98% take-rates, respectively, 
with both vaccines inducing neutralizing antibodies, albeit at 
higher titers for Dryvax®. Thus, Phase III trials confirmed the 
results of Phase II trials in that ACAM2000™ is as effective as 
Dryvax® for vaccination of vaccinia-naïve individuals, but that 
Dryvax® is superior to ACAM2000™ for revaccination. This 
phenomenon is most likely because of the decreased level of 
virulence of ACAM2000™ compared with Dryvax®, such that 
previously vaccinated individuals were more likely to mount 
an immune response sufficient to prevent viral replication of 
ACAM2000™ than that of Dryvax®.
Immunogenicity of ACAM2000™
With regard to induction of protective immune response, both 
humoral and cellular immune responses play important roles 
in protecting against poxvirus challenge in animal models 
and in clinical settings.26 Historically, antibody responses 
neutralizing virus at dilutions greater than 1:32 were shown to 
be crucial for protection against smallpox.27 The importance 
of antibody in protection is highlighted by the observation 
that vaccinia immune globulin can ameliorate complications 
from vaccination and can protect against smallpox infection.28 
Additionally, in the rhesus macaque monkeypox infection 
model, immune antibodies are required for protection against 
monkeypox and vaccine-induced antibodies alone are suf-
ficient for protection against challenge.18,19 ACAM2000™ 
vaccination resulted in a less robust antibody response 
than Dryvax® in one Phase I clinical trial (vaccinia-naïve), 
one of the two Phase II trials (vaccinia-experienced) and 
both Phase III trials (vaccinia-naïve and vaccinia-experi-
enced).6,24,29 While ACAM2000™ inoculation generally 
resulted in a four-fold increase in neutralizing antibodies, 
the titer was approximately 40% less than that of Dryvax®-
vaccinated individuals. Only one study, a Phase II clinical 
trial in vaccinia-naïve subjects, demonstrated a comparable 
antibody response between ACAM2000™ and Dryvax® 
groups.23 However, because most subjects vaccinated with 
ACAM2000™ developed the requisite four-fold increase in 
neutralizing antibodies, this would likely offer significant 
protection in the event of an exposure.
The importance of the cellular immune response in con-
trolling infection of poxviruses is made evident by individu-
als whose defective cellular immune response predisposes 
them to generalized vaccinia upon vaccination.30 Generally, 
Dryvax® vaccination stimulates CD4+ and CD8+ T-cell 
responses that are stable for decades.31,32 In a Phase I clinical Dovepress
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trial, ACAM2000™ and Dryvax® vaccination both induced 
positive responses in at least one assay for cell-mediated 
immunity in 100% and 93% of subjects, respectively.24
An issue that has not yet been addressed is that these 
studies were all done in adults (18 years and older), and the 
safety and efficacy of ACAM2000™ relative to Dryvax® is 
unknown in children. Additionally, studies of ACAM2000™ 
efficacy for post-exposure vaccination in animal models 
have not yet been reported in the literature. Administration 
of vaccinia virus within four days of exposure may offer 
protection based on historical clinical data from smallpox 
outbreaks.33 Nonetheless, Acambis received FDA approval 
for ACAM2000™ in 2007 and signed a 10-year contract with 
the US government in April 2008 for continued production 
for the US Strategic National Stockpile.
Adverse events with ACAM2000™
Vaccination against smallpox using live vaccinia virus has 
historically caused a number of different adverse events.2,34,35 
The adverse reactions range in severity and typically involve 
skin, eye, cardiac tissue, or in extremely rare cases, the 
nervous system. Cutaneous reactions include uticaria, rash, 
autoinoculation, eczema vaccinatum, generalized vaccinia, 
and progressive vaccinia (previously termed “vaccinia 
necrosum”). Ocular vaccinia is a common manifestation of 
auto-inoculation. Post-vaccinial encephalitis is a rare but 
potentially fatal complication. The rates of complications vary 
by age, with serious adverse events (SAEs) generally occur-
ring at a greater rate among the very young, particularly those 
less than 12 months old, than in older children and adults.
Whereas cardiac events had been reported in the literature 
before 2003, they were largely unrecognized during the 
  worldwide eradication campaign and were thought to occur 
very rarely. Only six cases of cardiac complications after 
smallpox vaccination with the NYCBH strain of vaccinia 
had been reported in the US before 2003.36 In the past 
decade, cardiac complications following live vaccinia 
  vaccination have been detected more often. This increase in 
  detection is because of the availability of more sophisticated 
  diagnostic techniques. Cardiac complications resulting 
from live vaccinia vaccination range in severity from mild 
to fatal and include myocarditis, pericarditis, arrhythmias, 
and dilated cardiomyopathy (DCM). Myocarditis is an 
inflammation of the heart muscle without blockage of the 
coronary arteries, and pericarditis is an inflammation of 
the fibrous sack surrounding the heart muscle. DCM is 
characterized by an enlarged and weakened heart muscle. 
Myocarditis and pericarditis, also collectively referred to 
as myopericarditis, can cause palpitations, shortness of 
breath, fever, sweats, or chest pain and can be diagnosed 
by an abnormal electrocardiogram (ECG), imaging studies 
  (echocardiogram), histopathology, or elevated cardiac 
enzymes. These inflammatory processes can be caused by 
a number of viral infections and autoimmune disorders, 
and have sequelae ranging from self-limiting asymptomatic 
  disease to DCM, resulting in fulminant congestive heart 
  failure and possibly death. Interestingly, myocarditis is 
blamed for causing up to 20% of all cases of sudden death 
among military recruits.37
To enhance preparedness in the event of an inten-
tional release of smallpox, a 2002 presidential initiative 
  recommended vaccination of enlisted military members, 
and voluntary participation for civilian health care workers 
with potential to be first responders. Military and civil-
ian populations were vaccinated with Dryvax® under 
the guidance of the Department of Defense (DOD) and 
the Department of Health and Human Services (HHS), 
respectively.38 By June of 2004, 39,566 civilians had been 
vaccinated, and by September 2006, more than 1.1 million 
soldiers were vaccinated. The occurrence of adverse events 
in both civilian and military populations was carefully 
  monitored.39,40 Compared with the historical rates of SAEs 
in the US reported before the 1970s, the rates of events such 
as generalized vaccinia and autoinoculation were compa-
rable. Cases of progressive vaccinia, eczema vaccinatum, 
and fetal vaccinia were completely avoided by careful 
screening of potential vaccinees, and attempting to limit 
vaccination to those without immunodeficiencies, eczema, or 
pregnancy. Among 730,580 DOD vaccinees, three cases of 
post-vaccinial encephalitis and 43 cases of mild generalized 
vaccinia occurred.41 Complications from vaccination were 
much less frequent in previously vaccinated individuals than 
those that were vaccinia-naïve.
While the frequencies of most SAEs were anticipated 
based on historical findings, a surprisingly large number of 
cardiac complications were reported in both civilian and mili-
tary cohorts in the 2003 vaccination campaign. One study that 
compared US soldiers who received live vaccinia vaccination 
with unvaccinated soldiers from South Korea showed a similar 
number of hospitalizations and cases of chest pain between 
the two groups, suggesting that the high rate of cardiac events 
was no greater than the baseline of a population.39 However, 
the occurrence of the vast majority of cardiac adverse 
events within 30 days of vaccination, and clustering within 
7–12 days post-vaccination, suggests a direct link between 
vaccination with live vaccinia virus and incidence of cardiac Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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complications.40 Of 730,580 US armed forces personnel 
vaccinated with Dryvax®, 86 cases of myopericarditis with 
moderate or severe clinical presentation occurred in other-
wise healthy vaccinees.42 The single fatal case of myocarditis 
was in a female. An earlier report calculated a rate of myo-
pericarditis 7.5-fold higher than the expected background rate 
among 347,516 primary vaccinees (56 cases, at a rate of 161 
per million).43 Of 37,901 HHS vaccinees, 21 civilians were 
diagnosed with myopericarditis (at a rate of 554 per million), 
all of which were mild cases that resolved without further 
complications.36 Additionally, four DOD and three HHS 
cases of DCM occurred among previously healthy subjects, 
with two requiring heart transplants.40
Ten patients among HHS vaccinees experienced ischemic 
cardiac events (ICEs), which are characterized as cardiac 
damage by a mechanism of constriction or blockage of blood 
flow. Seven of these patients had pre-existing cardiac risk 
factors, and two cases resulted in death.44 Of DOD vaccinees, 
16 cases of ICE occurred with three fatalities. The rates of 
cardiac events were so high within the first two months of 
the HHS vaccination program, the CDC formed a cardiac 
team to specifically monitor cardiac-related SAEs. From 
the time this correlation was recognized, patients were pre-
screened and those with at least three cardiac risk factors 
were deferred from vaccination. Possibly because of this 
screening, no additional ICEs were reported in the final 
6638 HHS vaccinees.
Serious and nonserious adverse events following 
  vaccination of 2983 people with ACAM2000™ (1307 naïve 
and 1676 experienced) were compared with that of Dryvax®.5 
With regard to overall common adverse events such as flu-like 
symptoms, lymph node pain, and reaction at the vaccination 
site, 99% of ACAM2000™ vaccinees had at least one adverse 
event compared with 100% of those receiving Dryvax®. 
In general, the individuals vaccinated with ACAM2000™ had 
a slightly lower, but statistically significant, incidence of 
several specific adverse events (including lymph node pain, 
injection site pain and pruritus). Additionally, the rates of 
flu-like symptoms among ACAM2000™-vaccinated subjects 
were lower for experienced vaccinees compared with the 
vaccinia-naïve group (55% versus 76%).5
With the higher than expected rate of cardiac compli-
cations in the HHS and DOD vaccination programs, the 
ACAM2000™ vaccine trials closely monitored patients by 
performing ECGs and serum tests for troponin I enzyme 
levels on all subjects in two Phase III clinical trials and in one 
Phase I clinical trial. The result was astounding in that people 
  vaccinated with either ACAM2000™ or Dryvax® had ECG 
and enzyme levels fitting a diagnosis of either myocarditis 
or pericarditis at a rate of more than 10 times that seen in 
the recent DOD and HHS vaccinations. In vaccinia-naïve 
subjects, myopericarditis occurred at a rate of 5730 per mil-
lion (seven cases in 1307 subjects) in ACAM2000™ vac-
cinees, and 1038 per million (three cases in 363 subjects) in 
Dryvax® vaccines respectively.5 No cases of myopericarditis 
occurred among 1819 vaccinia-experienced subjects vacci-
nated with either vaccine.40 The rates of myopericarditis for 
ACAM2000™ and Dryvax® were not statistically different in 
these trials.5 Thus, ACAM2000™ does not offer a significant 
reduction in cardiac adverse events compared with Dryvax®. 
A second important conclusion from these trials is that vac-
cination with either strain of NYCBH-derived live vaccinia 
virus results in a much higher rate of cardiac complications 
than previously thought, despite limiting enrollment into the 
studies to subjects with no known cardiac risk factors. The 
increased detection of adverse cardiac events can be attrib-
uted to the use of ECG and enzyme tests, as well as surveying 
for cardiac symptoms on post-vaccination questionnaires. 
Surveillance studies of adverse events after smallpox vac-
cination in the US in 1968 did not include questions related 
to possible cardiac events.45 Interestingly, many of the cases 
of myocarditis and pericarditis detected by the advanced 
screening were sub-clinical or asymptomatic.
In a Phase I clinical trial, 18.9% (17 of 90) of subjects 
vaccinated with Dryvax®, ACAM1000 or ACAM2000™ had 
a biologic false positive (BFP) syphilis test.46 The associa-
tion of smallpox vaccination with a BFP syphilis test result 
has long been known, and has been reported to occur in as 
few as 4% or as many as 45% of vaccine recipients.47,48 A 
BFP syphilis test result also occurs in many individuals with 
autoimmune disorders such as lupus, or infections such as 
HIV or parvovirus B19.49 Interestingly, patients with lupus 
or parvovirus B19 infections are predisposed to myocarditis 
and pericarditis as well as other cardiac complications.50,51 
The BFP syphilis test result indicates an individual has 
developed autoimmune antiphospholipid antibodies. Only a 
subset of ACAM2000™ or Dryvax® vaccinees with a BFP 
syphilis test result had myocarditis or pericarditis, and not all 
vaccinees with cardiac complications had a BFP syphilis test 
result. Thus, a direct correlation between antiphospholipid 
antibodies and myocarditis or pericarditis was not found 
among vaccinees; however, it is possible that the study was 
too small for the results to reach statistical significance. 
A causative role of antiphospholipid antibody responses and 
myocarditis and pericarditis has been reported for lupus.52 The 
possible association of vaccination, antiphospholipid antibod-Dovepress
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ies, and cardiac adverse events could reveal a mechanism by 
which live vaccinia vaccination causes cardiac damage and 
warrants further study. Of particular concern is that acute 
infectious myocarditis has been reported to result in lasting 
cardiac damage.53
The antiviral compound ST-246 inhibits viral replica-
tion in ACAM2000™-vaccinated mice.54 Another antiviral 
compound, cidofovir, reduced Dryvax® vaccination side 
effects in cynomolgus macaques, but also compromised the 
protection against monkeypox challenge.55 Thus, co-adminis-
tration of antiviral drugs may help reduce the frequency and 
severity of SAEs following vaccination with ACAM2000™ 
or other live vaccinia strains, but may also interfere with 
protective efficacy. Alternatively, a vaccine with a stronger 
safety profile, possibly attenuated vaccinia vaccines such 
as modified vaccinia Ankara (MVA), LC16m8, or subunit 
vaccine formulations, could be used as a first vaccination, 
followed by vaccination with ACAM2000™.
Conclusions
Vaccination with Dryvax® ended in 1972 for the public and 
in 1976 for health care workers, while the US military con-
tinued vaccination until 1989. The US vaccination policy 
changed in 2002, requiring vaccination for all military 
personnel and for “smallpox response teams” composed 
of civilian public health care staff. The remaining doses 
of Dryvax® were destroyed in 2008, with the national 
stockpile now consisting of over 200 million doses of 
ACAM2000™. Currently ACAM2000™ is used for all 
DOD personnel. Although ACAM2000™ has safety and 
efficacy data similar to that of Dryvax® in preclinical and 
clinical studies, there are still concerns related to SAEs, 
such as cardiac complications. In case of necessary global 
  vaccination after unintentional or intentional release of 
variola virus, as many as one in 145 vaccinees could be 
expected to develop myopericarditis, the seriousness of 
which is not entirely understood.40 In this event, meticulous 
screening, education of vaccinees, and co-administration 
of antiviral drugs, should greatly reduce the frequency 
and severity of SAEs. However, there is still a need for 
a safer smallpox vaccine for the general population and 
an alternative approach is especially needed for the large 
number of immunocompromised individuals, infants, and 
others with contraindications, for whom ACAM2000™ 
cannot be given.
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